AGE, TOTAL PSA, PSA DENSITY AND GLEASON SCORE, TAUS AS PREDICTIVE FACTORS IN PATIENTS WITH PROSTATE CANCER
Stacy L, Herbert B. Early detection, diagnosis, and staging of prostate cancer, in Campbell-Walsh Urology. 10th ed. Saunders: Philadelphia USA; 2012. p. 2764.
Bittner N, Gregory S, Andreini H, Taunbenslag W, Allen ZA, Butler WM, et al. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB. J Urol; 2009.
Giannarini G, Scott C, Moro U, Pertoldi B, Beltrami CA, Selli C. Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer. Urology Oncology: Seminars and Investigation; 2008. p. 353-60.
Stav K, Judith S, Merald H, Leibovici H, Lindner A, Zisman A. Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer. Urology Oncology; 2007. p. 382-86.
Andre N, Roemeling S, Kranse Ries, Scholder FH, Van Der Kwast TH. Should we replace the Gleason score with the amount of high-grade prostate cancer. European Association of Urology; 2007. p. 931-39.
Divrik RT, Eroglu A, Sahin A, Zorlu F, Ozen H. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens. Urology Oncology: Seminars and Investigation; 2007. p. 376-82.
Hong SK, Han BK, Lee ST, Kim SS, Min KE, Jeong SJ, et al. Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (¸12)-core prostate biopsy. J Urol; 2009. p. 271-76.
Munterner M, Epstein J, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E, et al. Prognostic Significance of Gleason Score Discrepancies between Needle Biopsy and Radical Prostatectomy. European Association of Urology; 2008. p. 767-76.
Alenda O, Ploussard G, Mouracade P, Xylinas E, Taille AD, Allory Yves, et al. Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors. J Urol; 2011. p. 671-76.
Rapiti E, Schaffar R, Iselin C, Mirabell R, Pelte MF, Weber D, et al. Importance and determinants of Gleason score undergrading on biopsy sample of prostate cancer in a population-based study. BMC Urology; 2011. p. 13-19.
Krane LS, Menon M, Kaul SA, Siddiqui SA, Wambi C, Peabody JO, et al. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer. Urology Oncology: Seminars and Investigation; 2011. p. 372-77.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.